Health and Healthcare

Bristol Myers Squibb : BMY

All Bristol Myers Squibb Articles

577 Articles

Jon C. Ogg | Mar 28, 2012 at 9:52 AM EDT

The Inevitable Amylin Buyout (AMLN, BMY, LLY, ALKS)

If there was a merger candidate which ever made sense in biotech and pharma it is Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN). …

Douglas A. McIntyre | Mar 2, 2012 at 6:37 AM EST

Media Digest (3/2/2012) Reuters, WSJ, FT, Bloomberg

Anheuser-Busch InBev NV may buy China’s Kingway Brewery Holdings’ assets. (Reuters) The Department of Justice is expected to widen its probe of mortgage-backed…

Jon C. Ogg | Feb 17, 2012 at 10:33 AM EST

Gilead Defended By Analyst As Competitors Gain Momentum (GILD, BMY, VRTX, ACHN)

Gilead Sciences, Inc. (NASDAQ: GILD) has recovered from its pre-market lows on the devastating news that its Hepatitis C drug…

Jon C. Ogg | Feb 13, 2012 at 4:17 PM EST

Drug & Biotech Makers Respond Unfavorably To Obama Budget Proposals (AMGN, BIIB, BMY, GSK, JNJ, MRK, PFE)

The Pharmaceutical Research and Manufacturers of America (PhRMA) has spoken out against the new 2013 budget proposed by President Obama. …

Paul Ausick | Jan 26, 2012 at 4:08 PM EST

24/7 Wall St. Closing Bell (GD, VALE, GMCR, GLW, CHK, ARG, ACAT, T, BMY, CAT, CY, LMT, MKC, MWW, POT, RTN, VIST, RNWK, MNTA, NFLX, EFSC)

All three major US indexes opened higher this morning, but enthusiasm tapered off quickly and steadily, if not sharply. A…

Jon C. Ogg | Jan 13, 2012 at 7:51 AM EST

Merger-Arbs Cleaning Up in Inhibitex Buyout (INHX, BMY)

It is not that often that investors get to clean up in a merger arbitrage spread any longer. The buyout…

Paul Ausick | Jan 11, 2012 at 1:37 PM EST

Pharma Value Beyond The Patent Expiration Cliff (PFE, MRK, BMY, TEVA, AMGN, GSK)

The tide of patent expirations that is washing over big pharmaceutical houses is cresting now and investors have begun looking…

Jon C. Ogg | Jan 10, 2012 at 3:47 PM EST

Achillion Pharma, Too Much of a Good Thing After 50% Gain? (ACHN, MRK, GILD, VRUS, BMY, INHX, VRTX)

Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) has been on fire due to the rapid interest of hepatitis C treatments and the bidding of…

Jon C. Ogg | Jan 9, 2012 at 11:11 AM EST

Hepatitis-C to the Moon (BMY, INHX, ACHN, IDIX, VRTX)

You know how stocks sometimes react to news on peers… Today we are again seeing a run in the world…

Paul Ausick | Jan 9, 2012 at 8:06 AM EST

Inhibitex Stock up 150% in Pre-Market (BMY, INHX)

Bristol-Myers Squibb (NYSE: BMY) will pay $2.5 billion in cash (a 163% premium to Friday’s closing price) for hepatitis C…

Douglas A. McIntyre | Jan 9, 2012 at 6:47 AM EST

What’s Important in the Financial World (1/9/2012) Chevy Volt Revivial, M&A Monday

Deal makers were busy over the weekend. Strategic considerations were more the driver of activity than an improved economy, however.…

Douglas A. McIntyre | Jan 9, 2012 at 6:46 AM EST

Media Digest (1/9/2012) Reuters, WSJ, NYT, FT, Bloomberg

http://platform.twitter.com/widgets/hub.1324331373.htmlThe U.S. may start legal proceedings against Swiss financial firm Wegelin & Co. based on beliefs that it helped shield…

Douglas A. McIntyre | Jan 8, 2012 at 5:07 PM EST